Level of Emotion
Conditions
Interventions
Remifentanil 0.2 µg/kg + Propofol 2 mg/kg (PR group):Anesthesia induction was performed using remifentanil 0.2 µg/kg and propofol 2 mg/kg. At the initiation of endoscopic procedures, the target sedati
Remifentanil 0.2 µg/kg + Ciprofol 0.4 mg/kg (CR group):Anesthesia induction was performed using remifentanil 0.2 µg/kg and ciprofol 0.4 mg/kg. At the initiation of endoscopic procedures, the target se
Remifentanil 0.2 µg/kg + Remimazolam 0.3 mg/kg (RR group):Anesthesia induction was performed using remifentanil 0.2 µg/kg and remimazolam 0.3 mg/kg. At the initiation of endoscopic procedures, the tar
Sponsors
Jiangsu Province Northern Jiangsu People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: (1) Painless gastroscopy and colonoscopy are planned to be performed; (2) No gender restrictions; (3) 18 years old = age = 65 years old; (4) ASA classification: I-II; (5) 18kg/m^2 =5 points (0-5 points, 6-9 points, 10-14 points, 15-21 points correspond respectively to no, mild anxiety, moderate anxiety and severe anxiety); (7) Informed consent, voluntary participation in this trial, and the informed consent form signed by the patient himself/herself.
Exclusion criteria
Exclusion criteria: (1) Complex or highly invasive endoscopic diagnostic and therapeutic techniques are required, such as foreign body removal in the upper digestive tract and esophageal stenosis dilation, etc. (2) Suffering from severe cardiovascular and cerebrovascular diseases, stroke, diabetes, etc. (3) Be determined to have difficulty in respiratory tract management; (4) Insufficiency of liver and kidney functions; (5) Previous history of suffering from other mental and neurological disorders (such as schizophrenia, mania, bipolar disorder, mental confusion, epilepsy, neuralgia, etc.) and taking corresponding treatment drugs for mental and neurological disorders (such as antidepressants, anti-anxiety drugs, convulsions, antiepileptic drugs, etc.) as well as cognitive dysfunction; (6) Allergic to or contraindicated to the investigational drug; (7) There is a disorder of speech and cognitive function; (8) Active infection (defined as white blood cell count > 10×10^9 or body temperature > 38?); (9) Long-term history of alcohol abuse; (10) History of drug abuse and drug use; (11) Pregnant women; (12) Having participated in clinical trials of other drugs or devices within three months prior to the screening period; (13) Refuse to participate in this research; (14) Those deemed inappropriate by the researchers.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of Emotion; | — |
Secondary
| Measure | Time frame |
|---|---|
| Level of Anxiety;Occurrence, severity, changes, and duration of euphoria ;Dreaming;Subjects' satisfaction with the quality of anesthesia;Short-term sleep patterns within 7 days post-surgery;Perioperative adverse events; | — |
Countries
China
Contacts
Public ContactGao Ju
Jiangsu Province Northern Jiangsu People's Hospital
Outcome results
None listed